

Current  
Eye Research

**Identification of surrogate biomarkers for the prediction of patients at risk of low macular pigment in Type 2 diabetes.**

Journal:	<i>Current Eye Research</i>
Manuscript ID	Draft
Manuscript Type:	Original Articles
Date Submitted by the Author:	n/a
Complete List of Authors:	Scanlon, Grainne; Technological University Dublin, Physics & Clinical & Optometric Sciences McCartney, Daniel; Technological University Dublin, School of Biological and Health Sciences Butler, John ; Technological University Dublin, Clinical & Optometric Sciences; Technological University Dublin, School of Mathematical Sciences Loskutova, Ekaterina; Technological University Dublin, School of Physics, Clinical & Optometric Sciences Loughman, James; Technological University Dublin, School of Physics, Clinical & Optometric Sciences
Keywords:	macular pigment, high density lipoprotein, triglycerides, overweight/obesity, vitamin D, inflammation, oxidative stress

SCHOLARONE™  
Manuscripts

1  
2  
3 **Title: Identification of surrogate biomarkers for the prediction of**  
4 **patients at risk of low macular pigment in Type 2 diabetes.**  
5  
6  
7  
8

9 **Authors:** Grainne Scanlon, MPhil <sup>1</sup>, Daniel McCartney, PhD <sup>2</sup>, John S  
10 Butler, PhD <sup>1,3</sup>, Ekaterina Loskutova, MD <sup>1</sup>, James Loughman, PhD <sup>1</sup>.  
11  
12  
13  
14

15 *Centre for Eye Research Ireland, School of Physics, Clinical & Optometric Sciences,*  
16 *Environmental Sustainability and Health Institute, Technological University Dublin,*  
17 *Grangegorman, Dublin 7, Ireland <sup>1</sup>.*  
18  
19  
20  
21

22 *School of Biological and Health Sciences, Technological University Dublin, City*  
23 *Campus, Kevin Street, Dublin 8, Ireland <sup>2</sup>.*  
24  
25  
26  
27

28 *School of Mathematical Sciences, Technological University Dublin, City Campus,*  
29 *Kevin Street, Dublin 8, Ireland <sup>3</sup>.*  
30  
31  
32  
33

34  
35  
36  
37  
38  
39  
40  
41  
42  
43 **Correspondence:** Grainne Scanlon. School of Physics, Clinical & Optometric Sciences,  
44 The National Optometry Centre, Kevin Street, Dublin 8, Ireland.  
45  
46  
47

48 Email: grainne.scanlon@dit.ie  
49

50 Phone number: +353 (0) 87 6868673; +353 (0) 1 4024933; Fax: +353 (0) 1 402 4915  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Title: Identification of surrogate biomarkers for the prediction of**  
4 **patients at risk of low macular pigment in Type 2 diabetes.**  
5  
6  
7  
8  
9

10 **Purpose:** This study compared macular pigment (MP) levels among persons with  
11 Type 2 diabetes relative to healthy controls. Additionally, a range of behavioral,  
12 anthropometric, clinical and serum measures were explored as possible predictors  
13 of low MP optical density (MPOD) in diabetes.  
14  
15  
16  
17

18 **Methods:** Two health status groups; Group 1: Type 2 diabetes (n=188), and  
19 Group 2: Healthy controls (n=2,594) completed a full MP assessment using  
20 customized heterochromatic flicker photometry, as part of The Irish Longitudinal  
21 Study on Aging (TILDA). Clinical [blood pressure; cataract status; MPOD] and  
22 anthropometric [waist (cm); weight (kg); hip (cm)] measurements were taken, and  
23 a blood sample drawn for analysis of serum biomarkers [lipoproteins;  
24 inflammatory markers (C reactive protein and vitamin-D)].  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 **Results:** One-way ANOVA revealed lower MPOD in subjects with Type 2  
35 diabetes relative to controls ( $p=0.047$ ). Amongst participants with diabetes, those  
36 with low serum vitamin D ( $\leq 50$  nmol/L) had significantly lower mean MPOD  
37 compared to those with sufficient serum vitamin D levels  $>50$  nmol/L  
38 (0.173(0.148) vs. 0.226(0.145);  $p=0.006$ ). Concomitantly, MP was significantly  
39 lower in diabetes participants with raised serum triglyceride (TG) to high density  
40 lipoprotein (HDL) ratio (TG/HDL); values  $>1.74$  mmol/L (0.172 (0.140) vs 0.215  
41 (0.152);  $p=0.039$ ). Body mass index, waist-to-height ratio and waist  
42 circumference, were all significantly negatively correlated with MPOD (Pearson's  
43 correlation,  $p<0.05$  for all). Significant correlates of MPOD in the multivariate  
44 regression model included smoking, cataract, and vitamin D, which collectively  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 contributed 18.5% of the overall variability in MPOD status amongst participants  
4  
5 with Type 2 diabetes.  
6

7 **Conclusions:** This study provides additional evidence that low MP may indeed be  
8  
9 a feature of Type 2 diabetes, and further identifies smoking, cataract and vitamin  
10  
11 D status as plausible predictors of low MPOD amongst persons with Type 2  
12  
13 diabetes.  
14  
15

16  
17 Key words: macular pigment, high density lipoprotein, triglycerides, vitamin D,  
18  
19 oxidative stress.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

The prevalence of diabetes has been increasing steadily over recent decades and is now reaching epidemic proportions <sup>1</sup>. Type 1 and Type 2 diabetes are the two main forms of diabetes, however, Type 2 diabetes is much more common and is estimated to affect more than 500 million people worldwide <sup>2</sup>. Diabetic retinopathy (DR), a debilitating microvascular complication of diabetes, is the most common cause of vision loss in people with diabetes and is a leading global cause of vision impairment and blindness among working-age adults <sup>3</sup>.

The pathogenesis of DR is multifactorial and remains poorly understood. Chronic hyperglycemia induces oxidative stress in the retina <sup>4</sup>, and it is thought that hyperglycemia leads to a dysregulation of inflammation, which in turn leads to an increase in the level of pro-inflammatory proteins <sup>5</sup>. Inflammatory processes underlie many of the functional retinal vasculature alterations observed histologically in early DR <sup>6</sup>. Animal and human studies have confirmed that all retinal cell types, including inner retinal neurons, Muller cells and astrocytes, are damaged by diabetes <sup>7</sup>.

Recognizing both the clinical and histological aspects of retinal change in diabetic macular edema and DR is essential to understanding the mechanisms of vision loss in diabetes, and in developing early-stage clinical interventions that effectively target the specific etiologies and underlying pathological mechanisms of the condition. In fact, insulin resistance, impaired glucose tolerance and Type 2 diabetes may exist for many years before clinical retinal signs become evident <sup>8</sup>.

The body's natural defence against oxidative damage and inflammation is the neutralization of reactive oxygen species (ROS) with endogenous antioxidants, both

1  
2  
3 enzymatic and non-enzymatic <sup>9</sup>. These endogenous antioxidants work with exogenous  
4 antioxidants (vitamin C, vitamin E and carotenoids such as beta carotene, lutein,  
5 zeaxanthin and *meso*-zeaxanthin) <sup>10</sup>, together balancing redox status. The carotenoids,  
6 lutein, zeaxanthin and *meso*-zeaxanthin, collectively known in the eye as macular  
7 pigment (MP); confer potent anti-oxidant and anti-inflammatory effects at the macula <sup>11</sup>.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<sup>12</sup>. These carotenoids are uniquely concentrated in the inner and central layers of the primate macula, and while the relationship between depleted MPOD and age-related macular degeneration (AMD) has been widely reported <sup>11</sup>, the association between diabetes and MPOD levels has received somewhat less attention.

The evidence that does exist, however, suggests that the relationship is worth exploring in more detail. Serum concentrations of lutein and zeaxanthin have been observed to be significantly lower in patients with DR <sup>13</sup>. Furthermore, MP has been found to be significantly lower in patients with diabetes <sup>14</sup>, with one study reporting lower levels of MP in Type 2 versus Type 1 patients <sup>15</sup>. It is also possible that MP may confer therapeutic benefits in diabetic eye disease. A number of studies have explored the effect of MP supplementation in diabetes. Although the evidence is far from definitive, improvements in structural and functional measures of ocular health in response to macular carotenoid supplementation have been found. The earliest of these studies reported improvements in vision and macular edema following supplementation <sup>13</sup>. The diabetes visual function supplement study (DiVFuSS) suggested that a nutritional supplement containing lutein and zeaxanthin mitigated the damaging effects of systemic inflammation on ocular function, and that these beneficial effects may have been mediated by enhancements in MPOD <sup>16</sup>. Improvements in visual function have also

1  
2  
3 been observed in patients with diabetes following supplementation, including in contrast  
4 sensitivity<sup>17</sup> and in electrophysiological indices of retinal function<sup>18</sup>.  
5  
6  
7  
8  
9

10 The reasons why MPOD levels might be adversely affected in diabetes are yet to be  
11 elucidated, but a number of factors might be important. At presentation, Type 2 diabetes  
12 is most often accompanied by other co-morbidities including overweight/obesity,  
13 insulin resistance, hypertension and dyslipidemia<sup>19</sup>. Excess adiposity, dyslipidemia  
14 (primarily reduced high density lipoproteins (HDL)) and hypertension, may adversely  
15 affect MP by compromising the availability<sup>20</sup>, transport<sup>21</sup>, assimilation<sup>21</sup> and  
16 maintenance/retention of dietary carotenoids in the retina. Adiposity, particularly  
17 abdominal fatness, may not only sequester dietary carotenoids<sup>20</sup> but may also act as an  
18 important mediator of inflammation, producing a variety of adipocytokines, including  
19 interleukin 1 (IL-1), interleukin 6 (IL 6), interleukin 8 (IL 8) and tumor necrosis factor  
20 alpha (TNF-alpha)<sup>5</sup>, which stimulate ROS synthesis and further compromise redox  
21 status. *De novo* synthesis of carotenoids is not possible in humans, therefore, the  
22 chronic low-grade inflammation<sup>5</sup> and pro-oxidative environment<sup>4</sup> associated with  
23 Type 2 diabetes may negatively impact MPOD levels in the eye.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 Macular pigment levels can be measured *in vivo*, but are not routinely measured in  
46 clinical practice. Given the possibility that higher levels of MP may be beneficial for  
47 vision and ocular health in diabetes, the investigation of surrogate indicators of MP  
48 status that are more readily and routinely measured is merited. The capacity of such an  
49 alternate biomarker to expedite the identification and treatment of patients at risk of low  
50 MP could be particularly important given that retinal damage can occur long before  
51 visual signs of DR are evident.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 This study was designed, therefore, to compare MPOD in participants with and without  
4 Type 2 diabetes and, more importantly, to explore a range of behavioral,  
5 anthropometric, clinical and serum biomarkers as possible predictors of risk for low  
6 MPOD among individuals with Type 2 diabetes.  
7  
8  
9  
10  
11  
12

## 13 **Methods**

### 14 ***Study Population***

15  
16  
17 The Irish Longitudinal Study on Ageing (TILDA) is a large prospective cohort  
18 study examining the social, economic and health factors which influence healthy ageing  
19 in older adults resident in Ireland<sup>22</sup>. Cross sectional data from TILDA was analyzed in  
20 this study. A stratified clustered sample of 8,175 individuals, representative of the  
21 population of Ireland, aged 50 years and over, participated in Wave 1 of this study,  
22 which took place between October 2009 and July 2011. The study design of TILDA has  
23 been described in detail elsewhere<sup>22</sup>. Health and lifestyle data were captured in  
24 participants' own homes using computerized aided personal interview (CAPI)<sup>23</sup>.  
25  
26 Participants were asked whether they had ever been told by a doctor if they had any of  
27 the following conditions: diabetes, high cholesterol, high blood pressure, AMD,  
28 cataracts or glaucoma. Participants were also asked to record all medications that they  
29 took on a regular basis, including those related to diabetes, such as oral hypoglycaemic  
30 agents (OHAs) and/or insulin, which were coded using the Anatomic Therapeutic  
31 Classification (ATC) system. Participants were asked if they currently smoked or had  
32 ever smoked cigarettes regularly (daily for at least a year), and were categorized as  
33 never smoked, past smokers or current smokers. The International Physical Activity  
34 Questionnaire (IPAQ) was used to classify participants' level of physical activity into  
35 low, moderate or high levels. All participants were invited to attend a health assessment  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 in one of two locations, Dublin or Cork. Macular pigment measurement was only  
4  
5 conducted on participants who attended a health centre, therefore, a number of  
6  
7 participants were automatically excluded from the current analysis: *i.e.* if they were  
8  
9 unable to travel to a health centre or opted for a home assessment instead (n=881)  
10  
11 and/or refrained from having either a home or health assessment (n=2,267). A total of  
12  
13 5027 individuals participated in a health assessment, carried out by trained research  
14  
15 nurses (Figure 1). This research adhered to the tenets of the Declaration of Helsinki and  
16  
17 was approved by the Technological University Dublin Research Ethics Committee. All  
18  
19 participants provided written informed consent prior to participation in the study.  
20  
21  
22  
23  
24

### 25 ***Diabetes Classification***

26  
27 Diabetes type was classified into ‘no diabetes’, ‘pre-diabetes’, ‘diagnosed diabetes’ and  
28  
29 ‘undiagnosed diabetes’. Diagnosed diabetes was identified from the CAPI with the  
30  
31 question ‘has a doctor ever told you that you have diabetes or high blood sugar?’ and  
32  
33 also from prescribed diabetes medications at the time of the interview, identified using  
34  
35 the ATC codes ‘A10A’ for insulin and ‘A10B’ for oral hypoglycemic medications. A  
36  
37 blood sample was provided for serum analysis. Glycated haemoglobin (HbA1c), a long-  
38  
39 term indicator of glycaemic control, was measured and participants were further  
40  
41 classified as having ‘pre-diabetes,’ and ‘undiagnosed diabetes’ against American  
42  
43 Diabetes Association cut-off values <sup>24</sup>. The TILDA protocol for blood sample  
44  
45 collection, processing and storage has been described previously <sup>23</sup>. Eleven respondents  
46  
47 who reported a doctors diagnosis of diabetes before the age of 40 and who were on  
48  
49 insulin therapy at the time of interview were excluded from analysis due to the  
50  
51 suspicion that they might have Type 1 diabetes, in line with previously published data  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 <sup>25</sup>, (Figure 1). Duration of disease was quantified by asking those with a previous  
4  
5 diagnosis ‘how old they were when first diagnosed?’  
6  
7

### 9 ***Macular Pigment Optical Density Assessment***

10  
11 Corrected visual acuity was measured in both eyes using the Early Treatment Diabetic  
12  
13 Retinopathy Study (ETDRS) LogMAR chart at a distance of 4 metres, using the  
14  
15 participants existing prescription where necessary. The eye with the best visual acuity  
16  
17 was chosen for the MP assessment or if there was equal vision in both eyes, the right  
18  
19 eye was chosen. MPOD was measured by customized heterochromatic flicker  
20  
21 photometry (c-HFP) centrally at 0.5° of retinal eccentricity using the Macular Metrics  
22  
23 Densitometer (Macular Metrics, Rehoboth, MA). The established method employed for  
24  
25 measuring MP has been described in detail previously <sup>26</sup>. Of the 5,027 participants who  
26  
27 attended a health assessment, 2,904 were able to successfully complete MPOD  
28  
29 assessment (participants with diabetes, n=310; non-diabetic controls, n=2,594). A  
30  
31 number of subjects were excluded from the overall MPOD analysis (n= 2,123) and  
32  
33 possible reasons for this included: poor fixation, technical issues, poor visual acuity  
34  
35 (visual acuity 6/18 Snellen ( $\leq 0.5$  LogMAR)) and retinal pathology (AMD, glaucoma).  
36  
37 Participants with pre-diabetes (HbA1c: 5.7 - 6.4%) or suspect Type 1 diabetes were also  
38  
39 excluded from the current analysis (n=122). Of the 8,500 participants that took part in  
40  
41 Wave 1 of TILDA, 188 Type 2 diabetes participants and 2,594 controls were deemed  
42  
43 suitable for the study (Figure 1).  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 **Insert Figure 1 Here:**  
54  
55  
56  
57  
58  
59  
60

### ***Anthropometric Assessment***

Height (cm) and weight (kg) were measured to one decimal place as described in detail elsewhere<sup>23</sup>. Body mass index (BMI) was calculated from measured height and weight as: weight (kg)/height (m<sup>2</sup>). Waist circumference (WC) and hip were measured to the nearest cm. Waist-to-height ratio (WHtR) and waist-to-hip ratio (WHpR) were calculated based on these measured data. Cut-offs were applied to classify participants as obese or non-obese for the following variables (BMI; WC; WHtR and WHpR)<sup>27</sup>.

### ***Blood Pressure***

Two blood pressure (BP) measurements were taken using the OMRON<sup>TM</sup> digital automatic blood pressure monitor (Model M10-IT) with arm cuff<sup>23</sup>. Seated mean systolic (mmHg) and mean diastolic (mmHg) BP were used for analysis. The participant was defined as hypertensive if mean seated systolic BP exceeded 140 mmHg or mean seated diastolic BP exceeded 90 mmHg.

### ***Serum Analysis***

Respondents were not asked to fast before the health assessment. Blood was extracted using defined phlebotomy protocols<sup>23</sup>, and analyzed for a complete lipid profile, which included total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL) and triglycerides (TG), measured in millimoles per litre (mmol/L). TG to HDL ratio, TC to HDL ratio and non-HDL cholesterol (TC minus HDL) were calculated for subsequent analyses. Cut-offs were applied to indicate high or ideal serum lipid levels as per 2016 European Society of Cardiology (ESC)/ European Atherosclerosis Society (EAS) guidelines<sup>28</sup>. Serum vitamin D levels [(25(OH)D); nanomoles per litre (nmol/L)] and the inflammatory marker C reactive protein (CRP), [micrograms per litre (mg/L)] were also measured. Respondents were considered vitamin D deficient if serum levels

1  
2  
3 were  $\leq 50$  nmol/L, and sufficient if serum levels were  $>50$  nmol/L as per the Institute of  
4  
5 Medicine (IOM) vitamin D guidelines <sup>29</sup>. A threshold of  $>3.00$ mg/L for high and  $\leq$   
6  
7 3.00mg/L as ideal was used for serum CRP <sup>30</sup>.  
8  
9

### 10 11 ***Statistical Analysis*** 12

13  
14 The statistical software package SPSS for Microsoft Windows (version 23.0; IBM  
15  
16 Corp., Armonk, NY) was used for all analyses. To account for the fact that the study  
17  
18 response rate varied among different subgroups of the population, inverse probability  
19  
20 weights were calculated for the main sample using the Quarterly National Household  
21  
22 Survey (2010) <sup>31</sup>. Participation rates for the health centre assessment also varied  
23  
24 according to geographic location, health, education, age and smoking, therefore a  
25  
26 specific “health centre weighting” was applied. A more detailed description of the  
27  
28 weighting procedure used in TILDA is described by Barrett et al <sup>31</sup>.  
29  
30  
31  
32

33  
34 Our data are presented as mean  $\pm$  standard deviation throughout. These data were tested  
35  
36 for normality using the Kolmogorov-Smirnov test. For group comparison between  
37  
38 participants with diabetes and non-diabetic controls, one-way analysis of variance  
39  
40 (ANOVA) was used to test for differences in means for normally distributed  
41  
42 parameters, while the Kruskal-Wallis test was used to test differences between group  
43  
44 medians for non-normally distributed parameters. For categorical data, cross-tabulation  
45  
46 with Chi-square analysis was used. The distribution of MPOD was skewed, therefore, a  
47  
48 square root transformation of the MPOD data was performed. The derived data were  
49  
50 normally distributed and used as the dependent variable for subsequent statistical  
51  
52 analyses of MPOD on the diabetes group. For ease of interpretation, mean and SD of  
53  
54 MPOD data is presented as the non-transformed original measure for Type 2 diabetes  
55  
56  
57  
58  
59  
60

1  
2  
3 participants. Pearson's product-moment correlation tests were performed to assess the  
4 relationship between normalized MPOD and other study variables where appropriate.  
5  
6 Boxplots and scatterplots were used to graphically highlight statistical findings.  
7  
8 Multiple linear regression was used to investigate the un-confounded associations  
9  
10 between behavioral, anthropometric, clinical and serum biomarker indicators and  
11  
12 normalized MPOD. The level of statistical significance was set at  $p < 0.05$  for all  
13  
14 analyses.  
15  
16  
17  
18  
19  
20

## 21 **Results**

22  
23 Two thousand seven hundred and eighty two subjects, analyzed as part of Wave 1 of  
24 TILDA, were divided into two study groups: Group 1: Normal controls (n=2,594) and  
25  
26 Group 2: Type 2 diabetes (n=188). Respondents 'diagnosed with diabetes' and those  
27  
28 with 'undiagnosed diabetes' were grouped together and classified as having Type 2  
29  
30 diabetes for subsequent analyses. Characteristics of the study population according to  
31  
32 their diabetes status are presented in Table 1. Group average MPOD was 10.3% lower  
33  
34 in participants with Type 2 diabetes [mean MPOD = 0.20(0.148)] compared with non-  
35  
36 diabetic controls [mean MPOD = 0.223(0.161)], and this difference was statistically  
37  
38 significant [ $t(2780) = -1.989, p = 0.047$ ]. Participants with Type 2 diabetes also differed  
39  
40 from the control group across all other demographic, behavioral, anthropometric,  
41  
42 clinical and serum parameters examined ( $p < 0.0001$  for all), with the exception of  
43  
44 education (primary, secondary or third level), alcohol intake, and serum TC to HDL  
45  
46 ratio ( $p > 0.05$  for these variables; Table 1).  
47  
48  
49  
50  
51

52  
53 Participants with diabetes were older, and more likely to be male with a current or past  
54  
55 history of tobacco use. In general terms, the behavioral, clinical and anthropometric  
56  
57 profile of these participants was poorer than that observed in the control group, with  
58  
59  
60

1  
2  
3 lower levels of physical activity, greater levels of obesity and higher prevalence of  
4  
5 hypertension and cataract. Similarly, serum analysis revealed that participants with  
6  
7 diabetes were typically more hyperglycemic, more dyslipidemic and displayed greater  
8  
9 inflammatory marker elevation than the control group.  
10  
11

12 **Insert Table 1 Here**  
13  
14  
15

### 16 ***Biomarker associations with MPOD among participants with diabetes*** 17 18

#### 19 ***(1) Demographic and Behavioral Factors*** 20 21

22 Smoking was the only demographic or behavioral factor significantly associated with  
23  
24 lower MPOD ( $F(2,185) = 6.019, p = 0.003$ ), as shown in Table 2. Post hoc analysis  
25  
26 revealed that participants who never smoked had significantly higher normalized  
27  
28 MPOD (mean=0.235(0.148)) compared with current smokers (mean=0.124(0.113);  $t$   
29  
30 (96);  $= 3.58, p = 0.001$ ). There was also a significant difference in MPOD between past  
31  
32 (mean=0.19[0.151] and current smokers ( $t(116); = 2.268, p = 0.025$ ). However, there  
33  
34 was no significant difference in MPOD between non-smokers and past smokers ( $t(158)$   
35  
36  $= 1.723, p = 0.087$ ); [Figure 2 (A)].  
37  
38  
39  
40  
41  
42

43 **Insert Table 2 Here**  
44  
45  
46

#### 47 ***(2) Anthropometric and Clinical Biomarkers*** 48 49

50 MPOD was negatively correlated with BMI; WC and WHtR (Pearson's correlation = -  
51  
52 0.202, -0.161, -0.189 respectively,  $p < 0.05$  for all), but not with WHpR (Pearson's  $r = -$   
53  
54 0.111,  $p > 0.05$ ). Although MPOD tended to be lower in subjects with cataracts, and in  
55  
56 those with elevated WHtR and WHpR (all trending towards significance), only  
57  
58  
59  
60

1  
2  
3 hypertension emerged in the univariate linear regression analysis as associated with  
4  
5 lower MPOD [Table 3; Figure 2 (B)].  
6  
7  
8  
9

10 **Insert Table 3 Here**  
11  
12

### 13 *(3) Serum Biomarkers*

14  
15  
16 MPOD was significantly lower among participants with a raised TG to HDL ratio  
17  
18 [Mean =0.172 (0.140)] compared to those with ideal levels (Mean =0.215(0.152); t  
19  
20 (185); = 2.080,  $p=0.039$ ; Table 4). Figure 2 (C) shows that participants with raised  
21  
22 TG/HDL (>1.74) had significantly lower MPOD compared with participants with  
23  
24 optimal TG/HDL ( $\leq 1.74$ ). ANOVA revealed no significant difference in MPOD  
25  
26 between those with high and low TC, HDL, LDL, triglycerides, non-HDL and TC/HDL  
27  
28 ( $p= 0.287-0.946$ ) (see Table 4). Participants who were vitamin D deficient had  
29  
30 significantly lower MPOD [mean = 0.173(0.148)] compared to participants who had  
31  
32 sufficient levels [mean = 0.226 (0.145); t (185), = -2.796,  $p=0.006$ ; Table 4; Figure 2  
33  
34 (D)]. Figure 3 shows a significant positive relationship between normalized MPOD and  
35  
36 serum vitamin D ( $r=0.218$ ,  $p=0.003$ ). There was no significant association between  
37  
38 MPOD and serum CRP levels (Table 4).  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 **Insert Table 4 Here**  
52  
53

54 **Insert Figure 2 (A) (B) (C) and (D) Here**  
55  
56

57 **Insert Figure 3 Here**  
58  
59  
60

## ***Multivariate Model***

### *Demographic and Behavioural Factors*

Smoking remained a strong, negative predictor of MPOD after adjusting for covariates. Current smoking was significantly associated with lower MPOD (Beta coefficient = -0.097;  $p=0.022$ ; Table 5).

### *Anthropometric and Physical Biomarkers*

The presence of cataract remained the only clinical parameter to be negatively associated with MPOD in a diabetic population after adjusting for covariates (Beta coefficient = -0.078;  $p<0.049$ ). None of the other anthropometric or clinical parameters (WHR, hypertension, diabetic retinopathy or duration of disease) remained significantly associated with MPOD in this model ( $p>0.05$  for all).

### *Serum Biomarkers*

Vitamin D remained a significant and positive predictor of MPOD in the multivariate model, although this was a subtle effect (Beta coefficient = 0.001;  $p=0.029$ ). None of the other serum biomarkers (TG/HDL, HbA1c or CRP) remained significantly associated with MPOD ( $p>0.05$  for these variables).

The correlates of MPOD identified as significant in the multivariate regression model (smoking, cataracts and low vitamin D status) contributed 18.5% of the overall variability in MPOD status amongst patients with Type 2 diabetes, ( $F(13,146) = 2.545$ ,  $p=0.003$ ;  $R^2 = 0.185$ ).

**Insert Table 5 Here**



## Discussion

Consistent with previous investigations<sup>14, 15</sup>, this study provides further evidence that patients with Type 2 diabetes have significantly lower MPOD, compared with non-diabetic controls. Additionally, MPOD was inversely associated with a range of behavioral, clinical and anthropometric biomarkers including smoking, hypertension and bodyweight. Body mass index, WHtR and WC were all negatively associated with MPOD on univariate analysis, in the Type 2 diabetes group. Some novel relationships were observed among the serum biomarkers, with low serum vitamin D and raised TG/HDL ratio associated with low MPOD levels; findings not previously reported. Current smoking, the presence of cataract and low serum vitamin D persisted as predictors of low MPOD in the multivariate model, after adjusting for all other covariates, albeit collectively explaining just 18.5% of the variability in MPOD.

Our finding that hypertensive participants with diabetes had significantly lower MPOD compared to normotensive participants with diabetes is important given that hypertension is an established risk factor for the development and progression of DR<sup>33</sup>. The association between MP and hypertension is not well documented; however, one study has reported a link between lower MPOD and a self-reported diagnosis of high blood pressure<sup>32</sup>. Chronic hypertension causes vascular endothelial shear stress and circumferential wall stress<sup>34</sup>. This, in turn, leads to endothelial damage, increased ROS production and activation of inflammatory cascades<sup>35</sup>. One recent study found lower levels of glutathione (GSH) and increased levels of 8-iso-prostaglandin 2 $\alpha$  (8-iso-PGF2 $\alpha$ ), a marker of oxidative stress, in diabetes patients with hypertension, supporting the hypothesis that oxidative stress increases considerably in hypertension, especially as a diabetic co-morbidity<sup>36</sup>. Endogenous antioxidants become depleted when both

1  
2  
3 conditions coexist, which leads to an increased need for exogenous antioxidants (*i.e.*  
4 vitamins C and E, carotenoids lutein, zeaxanthin & *meso*-zeaxanthin) to balance redox  
5 status, which may explain our observation that hypertension in the presence of Type 2  
6 diabetes may have an added negative impact on MPOD status.  
7  
8  
9

10  
11  
12  
13  
14 The inverse relationship observed between adiposity and MPOD confirms previous  
15 findings among patients with Type 2 diabetes<sup>15, 20</sup>. Adipose tissue, visceral fat in  
16 particular; may act as a sink/reservoir for macular carotenoids<sup>20</sup>, thereby influencing  
17 carotenoid concentrations in serum<sup>37</sup> and subsequent retinal uptake<sup>21</sup>. Distribution of  
18 body fat is also a significant factor, as it has been shown that concentrations of lutein  
19 and zeaxanthin are higher in abdominal fat<sup>38</sup>, and abdominal adiposity is characteristic  
20 in Type 2 diabetes. Excess visceral fat also contributes to inflammation and oxidative  
21 stress due to the increased production of adipo-cytokines (IL-1, IL-6, IL-8, TNF-alpha),  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Of interest, and to our knowledge a novel finding; is that MPOD was significantly lower  
for participants with a raised TG to HDL ratio. This observation is important given that  
Type 2 diabetes patients commonly display an altered lipoprotein profile, termed  
diabetic dyslipidemia (*i.e.* raised TGs and low HDL), and that diabetes patients in the  
current study had indeed significantly higher TGs and significantly lower HDL serum  
lipid levels than the non-diabetic control group. The characteristic lipid profile of  
individuals with Type 2 diabetes<sup>40</sup> may have important implications for MP levels in  
the eye, as dietary carotenoids are transported on circulating lipoproteins<sup>21</sup>. The general  
consensus is that xanthophylls associate with HDL<sup>41</sup>, and that HDL levels are therefore  
important for the efficient delivery and uptake of lutein and zeaxanthin to the eye<sup>21</sup>.

1  
2  
3 The relationship between MPOD and serum lipid levels has previously been  
4 investigated in patients with diabetes, with a marginal negative association between  
5 MPOD and TGs and a marginal positive association between MPOD and HDL  
6 observed ( $p < 0.08$  for both)<sup>14</sup>. We previously reported significantly lower levels of  
7 MPOD in patients with Type 2 versus Type 1 diabetes, and noted significantly lower  
8 HDL values within the Type 2 diabetes group, postulating that lower HDL levels may  
9 have mediated this difference<sup>15</sup>. More recently, the DiVFuSS study<sup>16</sup>, has  
10 demonstrated significant improvements in serum LDL, HDL and TGs, in a group of  
11 patients with diabetes who participated in a 6-month randomized control trial (RCT).  
12 The coincident increase in MPOD observed in the intervention group may have been  
13 partially mediated by these favourable changes in lipid profile<sup>21</sup>.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 Our findings in relation to smoking are not surprising given that smoking is associated  
32 with increased oxidative stress, not only through the increased systemic production of  
33 ROS, but also through weakening of the antioxidant defence systems<sup>42</sup>. The reported  
34 associations between cigarette smoking and DR, however, are more variable, with some  
35 studies reporting an association<sup>43</sup>, while others have found no such relationship<sup>44</sup>.  
36  
37 Chronic hyperglycemia causes oxidative stress, so the increased production of ROS in  
38 diabetes may be compounded further by smoking, another important source of free  
39 radicals. Exposure to cigarette smoking causes profound oxidative damage to human  
40 retinal pigment epithelium (RPE) cells<sup>45</sup>. Interestingly, we found no difference in  
41 MPOD between previous smokers and non-smokers, perhaps indicating that MPOD  
42 repletion is possible in diabetes patients through smoking cessation.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Cataract status remained a predictor of low MPOD in the multivariate model in line  
4  
5 with previous observations <sup>46, 47</sup>. The marginal statistical significance of this association  
6  
7 in the univariate model ( $p=0.068$ ) was more than likely limited by the small sample size  
8  
9 in the current study ( $n=26$  with cataracts). The evidence that carotenoids, lutein and  
10  
11 zeaxanthin, are protective against the development of cataract, however, is well  
12  
13 documented <sup>46, 47</sup>, suggesting the possibility of a causal role for MPOD depletion in the  
14  
15 pathogenesis of cataract development in diabetes. This is supported by previous data  
16  
17 describing a lower prevalence of nuclear cataract amongst those with higher intakes of  
18  
19 xanthophylls <sup>47</sup>. Furthermore, findings from the age related eye disease study (AREDS  
20  
21 2) revealed that participants in the lowest quintile of dietary lutein/zeaxanthin intake  
22  
23 experienced slower cataract progression with carotenoid supplementation <sup>46</sup>. Although  
24  
25 the development of cataract is an age-related phenomenon, other factors appear to  
26  
27 influence their progression including poor diet, smoking, ultra violet light exposure and  
28  
29 metabolic factors. In the current study, a greater percentage of patients with diabetes  
30  
31 had cataract (13.83%) compared with controls (6.51%), ( $p<0.0001$ ). Cataract status  
32  
33 does not appear to relate to MPOD levels among non-diabetic individuals <sup>32</sup>, suggesting  
34  
35 a relationship that is particular to cataract in the presence of Type 2 diabetes which may  
36  
37 impact MPOD levels in this patient group. To our knowledge, this is the first study to  
38  
39 report an association between low MPOD and the development of cataract in diabetes.  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 That vitamin D emerged as a positive predictor of MPOD in Type 2 diabetes after  
50  
51 controlling for other covariates represents a particularly novel and interesting finding.  
52  
53 Although the best known function of vitamin D is to help the body absorb and use  
54  
55 calcium, other important roles include protection of the eye during inflammation,  
56  
57 oxidative stress, fibrosis, and angiogenesis <sup>48</sup>. Vitamin D insufficiency is common  
58  
59  
60

1  
2  
3 amongst the general population, and particularly amongst those who are obese<sup>49</sup> or who  
4 have diabetes<sup>50</sup>. Our findings support this observation as both the control and Type 2  
5 diabetes group had mean vitamin D levels which fell well below the optimal  
6 recommended level<sup>51</sup>, and as the participants with Type 2 diabetes had significantly  
7 lower serum vitamin D compared with the control group ( $p < 0.0001$ ). Vitamin D  
8 receptors (VDRs) are expressed in the eye, including the RPE<sup>52</sup> which suggests that  
9 vitamin D is biologically relevant to the eye<sup>53</sup>. Research shows that human adult RPE  
10 cells (ARPE-19) also express the  $1\alpha$ -hydroxylase enzyme required to convert 25(OH) D  
11 to its biologically active  $1,25(\text{OH})_2 \text{D}$  form<sup>54</sup>.

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26 The ability to inhibit neovascularisation has also led researchers to examine vitamin D's  
27 involvement in DR development<sup>55</sup>. Serum vitamin D concentrations have previously  
28 been found to be inversely related to the severity of retinopathy in patients with diabetes  
29 <sup>53</sup>, with this study suggesting that the measurement of serum  $1,25(\text{OH})_2 \text{D}_3$   
30 concentrations might be helpful in predicting retinopathy progression, and that a  
31 detailed ophthalmologic examination is indicated for diabetes patients whose serum  
32 vitamin D levels are low<sup>53</sup>. The DiVFuSS study recently examined the effects of  
33 supplementation with a novel multi-component nutritional supplement, which included  
34 vitamin D and the antioxidants lutein and zeaxanthin, on ocular health and visual  
35 function in a group of participants with diabetes<sup>16</sup>. Individuals receiving the DiVFuSS  
36 formula improved on all measures of visual function, and although not statistically  
37 significant ( $p = 0.07$ ), four subjects were downgraded from moderate to mild non  
38 proliferative DR following the intervention, while one subject on placebo was upgraded  
39 from mild to moderate non proliferative DR over the same period<sup>16</sup>. Positive outcomes  
40 from DiVFuSS may in part be due to supplementation with a compound that

1  
2  
3 specifically targets both inflammation and oxidative stress. It is plausible that these  
4 findings may have been mediated by enhancements in MPOD (27% mean increase in  
5 DiVFuSS group vs 2% mean decrease in placebo group), and by vitamin D's  
6 attenuating effect on inflammation with reductions in serum high sensitivity (hs)-CRP  
7 (60% mean decrease in DiVFuSS group vs 11% mean decrease in placebo group) <sup>16</sup>.  
8  
9  
10  
11  
12  
13  
14  
15  
16

17 There are a number of important limitations to the current study which should be  
18 recognised. Firstly, the use of self-reported data is not ideal. Diabetes diagnosis was  
19 based on respondent's recall rather than health records. Concomitantly, respondents  
20 were not explicitly asked what type of diabetes they had. Instead patient medications  
21 (self-reported) and age at diagnosis were used to account for possible Type 1 cases,  
22 which may have led to some misclassification. Secondly, small patient numbers in some  
23 of the sub-group analyses may have limited the statistical power to detect associations  
24 that may exist (Type II error possibility). It is worth noting that the prevalence of  
25 diagnosed and undiagnosed Type 2 diabetes in these older adults resident in Ireland was  
26 found to be relatively low compared to other populations (8.6% and 0.9% respectively),  
27 which would account for low participant numbers in the current study <sup>8, 25</sup>. Another  
28 limitation was that dietary intake of the macular carotenoids was also not assessed,  
29 therefore, it was not possible to control for potential confounding from variable intake  
30 of lutein and zeaxanthin. The MP determinants reported herein (current smoking,  
31 presence of cataracts and vitamin D status) explained 18.5% of the overall variability in  
32 MPOD, in participants with diabetes. Dietary information, however, would have added  
33 to the interpretation of our findings as *de-novo* synthesis of MP is not possible in  
34 mammals. The absence of serum analysis of lutein and zeaxanthin was also a weakness.  
35 Diet is an important determinant of MPOD, therefore, cautionary interpretation of our  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 findings is advised. Finally, while the current study used a large, nationally  
4  
5 representative population, MPOD was only measured on participants who were able to  
6  
7 attend a health center.  
8  
9

10  
11  
12 Despite these drawbacks, there were a number of strengths to the current analysis. The  
13  
14 design of the TILDA study is a particular strength, in particular the selection of  
15  
16 participants from which our diabetes and controls were drawn, which was representative  
17  
18 of the Irish population aged 50 and over. Serum lipoproteins (HDL, TG/HDL) and  
19  
20 inflammatory markers (vitamin D, CRP) were analyzed and blood pressure was  
21  
22 measured, which represents an advance on previous research carried out, research which  
23  
24 was based on self-reported doctors' diagnosis of high cholesterol and hypertension <sup>32</sup>.  
25  
26 The additional use of HbA1c helped identify undiagnosed and pre-diabetes cases.  
27  
28 Finally, anthropometric measures such as WtHtR and WHpR, were used to analyse  
29  
30 overweight/obesity in conjunction with BMI and WC.  
31  
32  
33  
34  
35  
36  
37

38 Overall our findings suggest that individuals with Type 2 diabetes have lower MP  
39  
40 relative to healthy controls. Hyperglycemia and other anthropometric, metabolic and  
41  
42 clinical correlates associated with diabetes (e.g. excess adiposity, dyslipidemia,  
43  
44 hypertension, and cataract), may relate to a state of chronic oxidative stress and  
45  
46 inflammation, processes which also underlie many of the functional alterations in retinal  
47  
48 vasculature in DR. Both over utilization (*i.e.* in response to elevated oxidative  
49  
50 stress/inflammation) and under supply of antioxidant nutrients (dietary deficiency,  
51  
52 excess adiposity, and dyslipidemia) may contribute to lower levels of MP in the diabetic  
53  
54 retina. Clinical benefits may be realised through the early identification of MPOD  
55  
56 depletion in Type 2 diabetes. Given the borderline statistical significance of many of  
57  
58  
59  
60

1  
2  
3 our findings, more work needs to be done to verify and refine our understanding of the  
4  
5 observed relationships. The MPOD difference of 0.053 OD in participants with  
6  
7 sufficient vitamin D ( $>50\text{nmol/L}$ ) versus deficient levels ( $\leq 50\text{ nmol/L}$ ), although  
8  
9 significant ( $p<0.006$ ), is not clinically meaningful as it stands. MPOD measurement is  
10  
11 not routinely available, however, the capacity of commonly-measured surrogate serum  
12  
13 biomarkers (HDL, TG/HDL, vitamin D), and anthropometric measurements (WHtR,  
14  
15 WC) to identify people with diabetes at risk of low MP merits further consideration.  
16  
17 The novel and important findings reported herein should now be subject to further  
18  
19 research, to better understand the nature of any relationships that may exist.  
20  
21  
22  
23  
24  
25

26 **Acknowledgements:** The authors would like to thank The Irish Longitudinal Study on  
27  
28 Aging (TILDA) for the support received and are grateful to all of the TILDA  
29  
30 respondents for participating in the study.  
31  
32  
33

34 **Declaration of interest:**

35  
36  
37 No potential conflict of interest was reported by the authors.  
38  
39  
40

41 **Funding:** None  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## References

1. Carracher AM, Marathe PH, Close KL. International Diabetes Federation 2017. *J Diabetes* 2018;10:353-356.
2. Kaiser AB, Zhang N, Van Der Plumm W. Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028). *Am Diabetes Assoc* 2018.
3. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. *Eye Vis* 2015;2:17.
4. Kowluru RA, Chan P-S. Oxidative stress and diabetic retinopathy. *J Diabetes Res* 2007;2007: 43603.
5. Kwon H, Pessin J. Adipokines mediate inflammation and insulin resistance *Front Endocrinol* 2013;4:71.
6. Semeraro F, Cancarini A, Rezzola S, Romano M, Costagliola C. Diabetic retinopathy: vascular and inflammatory disease. *J Diabetes Res* 2015;2015: 582060. doi: 10.1155/2015/582060.
7. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. *J Clin Invest* 1998;102:783-791.
8. Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults. *Diabetes Res Clinic Practice* 2014;103:150-160.
9. Sies H. Oxidative stress: from basic research to clinical application. *Am J Med* 1991;91:S31-S38.
10. Bouayed J, Bohn T. Exogenous antioxidants—double-edged swords in cellular redox state: health beneficial effects at physiologic doses versus deleterious effects at high doses. *Oxidative Med Cellular Longevity* 2010;3:228-237.

- 1  
2  
3 11. Chew EY, Clemons TE, SanGiovanni JP, Danis R, Ferris FL, Elman M,  
4  
5 Antoszyk A, Ruby A, Orth D, Bressler S. Lutein+ zeaxanthin and omega-3 fatty  
6  
7 acids for age-related macular degeneration: the Age-Related Eye Disease Study  
8  
9 2 (AREDS2) randomized clinical trial. *JAMA-Journal of the American Medical*  
10  
11 *Association* 2013;309:2005-2015.
- 12  
13  
14 12. Li S-Y, Fung FK, Fu ZJ, Wong D, Chan HH, Lo AC. Anti-Inflammatory Effects  
15  
16 of Lutein in Retinal Ischemic/Hypoxic Injury: In Vivo and In Vitro StudiesAnti-  
17  
18 Inflammatory Effects of Lutein. *Invest Ophthalmol Vis Sci* 2012;53:5976-5984.
- 19  
20  
21 13. Hu B-J, Hu Y-N, Lin S, Ma W-J, Li X-R. Application of lutein and zeaxanthin  
22  
23 in nonproliferative diabetic retinopathy. *Int J Ophthalmol* 2011;4:303.
- 24  
25  
26 14. Lima VC, Rosen RB, Maia M, Prata TS, Dorairaj S, Farah ME, Sallum J.  
27  
28 Macular pigment optical density measured by dual-wavelength autofluorescence  
29  
30 imaging in diabetic and nondiabetic patients: a comparative study. *Invest*  
31  
32 *Ophthalmol Vis Sci* 2010;51:5840-5845.
- 33  
34  
35 15. Scanlon G, Connell P, Ratzlaff M, Foerg B, McCartney D, Murphy A, O'Connor  
36  
37 K, Loughman J. Macular pigment optical density is lower in type 2 diabetes,  
38  
39 compared with type 1 diabetes and normal controls. *Retina* 2015;35:1808-1816.
- 40  
41  
42 16. Chous AP, Richer SP, Gerson JD, Kowluru RA. The diabetes visual function  
43  
44 supplement study (DiVFuSS). *Br J Ophthalmol* 2016;100:227-34.
- 45  
46  
47 17. Crosby-Nwaobi R, Hykin P, Peto T, Sivaprasad S. An exploratory study  
48  
49 evaluating the effects of macular carotenoid supplementation in various retinal  
50  
51 diseases. *Clinic Ophthalmol (Auckland, NZ)* 2016;10:835.
- 52  
53  
54 18. Moschos MM, Dettoraki M, Tsatsos M, Kitsos G, Kalogeropoulos C. Effect of  
55  
56 carotenoids dietary supplementation on macular function in diabetic patients.  
57  
58 *Eye Vis* 2017;4:23.
- 59  
60

- 1  
2  
3 19. Castro AVB, Kolka CM, Kim SP, Bergman RN. Obesity, insulin resistance and  
4 comorbidities? Mechanisms of association. *Arquivos Brasileiros de*  
5  
6 *Endocrinologia & Metabologia* 2014;58:600-609.  
7  
8
- 9  
10 20. Hammond BR, Ciulla TA, Snodderly DM. Macular pigment density is reduced  
11  
12 in obese subjects. *Invest Ophthalmol Vis Sci* 2002;43:47-50.  
13
- 14 21. Connor WE, Duell PB, Kean R, Wang Y. The prime role of HDL to transport  
15  
16 lutein into the retina: evidence from HDL-deficient WHAM chicks having a  
17  
18 mutant ABCA1 transporter. *Invest Ophthalmol Vis Sci* 2007;48:4226-4231.  
19
- 20 22. Kearney PM, Cronin H, O'regan C, Kamiya Y, Savva GM, Whelan B, Kenny R.  
21  
22 Cohort profile: the Irish longitudinal study on ageing. *Internat J Epidemiol*  
23  
24 2011;40:877-884.  
25
- 26 23. Kenny RA, Whelan BJ, Cronin H, Kamiya Y, Kearney P, O'Regan C, Ziegel M.  
27  
28 The design of the Irish longitudinal study on ageing. 2010  
29
- 30 24. Association AD: 2. Classification and diagnosis of diabetes. *Diabetes care*  
31  
32 2015;38:S8-S16.  
33
- 34 25. Leahy S, O'Halloran A, O'Leary N, Healy M, McCormack M, Kenny R,  
35  
36 O'Connell J. Prevalence and correlates of diagnosed and undiagnosed type 2  
37  
38 diabetes mellitus and pre-diabetes in older adults: Findings from the Irish  
39  
40 Longitudinal Study on Ageing (TILDA). *Diabetes research and clinical practice*  
41  
42 2015;110:241-249.  
43  
44
- 45 26. Nolan JM, Kenny R, O'Regan C, Cronin H, Loughman J, Connolly EE, Kearney  
46  
47 P, Loane E, Beatty S. Macular pigment optical density in an ageing Irish  
48  
49 population: The Irish Longitudinal Study on Ageing. *Ophthalmic Res*  
50  
51 2010;44:131-139.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 27. Organization WH. Waist circumference and waist-hip ratio: report of a WHO  
4 expert consultation, Geneva, 8-11 December 2008; (2011).  
5  
6  
7  
8 28. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H,  
9  
10 Hoes AW, Jennings CS, Landmesser U, Pedersen TR. 2016 ESC/EAS  
11  
12 guidelines for the management of dyslipidaemias. *Eur Heart J* 2016;37:2999-  
13  
14 3058.  
15  
16  
17 29. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-  
18  
19 Arvizu RA, Gallagher JC, Gallo RL, Jones G et al. The 2011 report on dietary  
20  
21 reference intakes for calcium and vitamin D from the Institute of Medicine: what  
22  
23 clinicians need to know. *J Clin Endocrinol Metab* 2011;96:53-58.  
24  
25  
26 30. Koenig W, Sund M, Fröhlich M, Fischer H-G, Löwel H, Döring A, Hutchinson  
27  
28 WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation,  
29  
30 predicts future risk of coronary heart disease in initially healthy middle-aged  
31  
32 men: results from the MONICA (Monitoring Trends and Determinants in  
33  
34 Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. *Circulation*  
35  
36 1999;99:237-242.  
37  
38  
39  
40 31. Barrett A, Burke H, Cronin H, Hickey A, Kamiya Y, Kenny RA, Layte R, Maty  
41  
42 S, McGee H, Morgan K. Fifty plus in Ireland 2011. first results from the Irish  
43  
44 Longitudinal Study on Ageing (TILDA). 2011  
45  
46  
47 32. Nolan JM, Feeney J, Kenny RA, Cronin H, O'Regan C, Savva GM, Loughman  
48  
49 J, Finucane C, Connolly E, Meagher K. Education Is Positively Associated with  
50  
51 Macular Pigment: The Irish Longitudinal Study on Ageing (TILDA) Education  
52  
53 and The TILDA Study. *Invest Ophthalmol Vis Sci* 2012;53:7855-7861.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 33. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Is blood pressure a  
4 predictor of the incidence or progression of diabetic retinopathy? *Arch Internal*  
5 *Med* 1989;149:2427-2432.  
6  
7  
8  
9  
10 34. Lu D, Kassab GS. Role of shear stress and stretch in vascular mechanobiology. *J*  
11 *Royal Soc Interface* 2011;8:1379-1385.  
12  
13  
14 35. Crowley SD. The cooperative roles of inflammation and oxidative stress in the  
15 pathogenesis of hypertension. *Antioxidants Redox Signaling* 2014;20:102-120.  
16  
17  
18 36. Pouvreau C, Dayre A, Butkowski EG, de Jong B, Jelinek HF. Inflammation and  
19 oxidative stress markers in diabetes and hypertension. *J Inflamm Res*  
20 2018;11:61.  
21  
22  
23  
24 37. Burke JD, Curran-Celentano J, Wenzel AJ. Diet and serum carotenoid  
25 concentrations affect macular pigment optical density in adults 45 years and  
26 older. *J Nutr* 2005;135:1208-1214.  
27  
28  
29 38. Chung H-Y, Ferreira ALA, Epstein S, Paiva SA, Castaneda-Sceppa C, Johnson  
30 EJ. Site-specific concentrations of carotenoids in adipose tissue: relations with  
31 dietary and serum carotenoid concentrations in healthy adults. *Am J Clin Nutr*  
32 2009;90:533-539.  
33  
34  
35 39. Bovier ER, Lewis RD, Hammond BR. The relationship between lutein and  
36 zeaxanthin status and body fat. *Nutrients* 2013;5:750-757.  
37  
38  
39 40. Goldberg IJ. Diabetic dyslipidemia: causes and consequences. *J Clin*  
40 *Endocrinol Metab* 2001;86:965-971.  
41  
42  
43 41. Thomas SE, Harrison EH. Mechanisms of selective delivery of xanthophylls to  
44 retinal pigment epithelial cells by human lipoproteins. *J Lipid Res*  
45 2016;57:1865-78.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 42. Isik B, Ceylan A, Isik R. Oxidative stress in smokers and non-smokers.  
4  
5 *Inhalation Toxicology* 2007;19:767-769.  
6  
7  
8 43. Abdul-Ridha H. The Effect of Smoking on Some Microvascular Complications  
9  
10 in Type 2 Diabetics. *Mustansiriya Med J* 2010;9:35-39.  
11  
12 44. Klein R, Klein BE, Davis MD. Is cigarette smoking associated with diabetic  
13  
14 retinopathy? *Am J Epidemiol* 1983;118:228-238.  
15  
16  
17 45. Bertram KM, Baglole CJ, Phipps RP, Libby RT. Molecular regulation of  
18  
19 cigarette smoke induced-oxidative stress in human retinal pigment epithelial  
20  
21 cells: implications for age-related macular degeneration. *Am J Physiol-Cell*  
22  
23 *Physiol* 2009;297:C1200-C1210.  
24  
25  
26 46. Chew EY, SanGiovanni JP, Ferris FL, Wong WT, Agron E, Clemons TE,  
27  
28 Sperduto R, Danis R, Chandra SR, Blodi BA. Lutein/zeaxanthin for the  
29  
30 treatment of age-related cataract: AREDS2 randomized trial report no. 4. *JAMA-*  
31  
32 *Journal of American and Medical Association* 2013;131:843-850.  
33  
34  
35 47. Jacques PF, Chylack LT, Hankinson SE, Khu PM, Rogers G, Friend J, Tung W,  
36  
37 Wolfe JK, Padhye N, Willett WC Taylor A. Long-term nutrient intake and early  
38  
39 age-related nuclear lens opacities. *Arch Ophthalmol* 2001;119:1009-1019.  
40  
41  
42 48. Reins RY, McDermott AM. Vitamin D: implications for ocular disease and  
43  
44 therapeutic potential. *Exp Eye Res* 2015;134:101-110.  
45  
46  
47 49. Alaklabi AM, Alsharairi NA. Current Evidence on Vitamin D Deficiency and  
48  
49 Metabolic Syndrome in Obese Children: What Does the Evidence from Saudi  
50  
51 Arabia Tell Us? *Children (Basel)* 2018;5:11.  
52  
53  
54 50. Bayani MA, Akbari R, Banasaz B, Saeedi F. Status of Vitamin-D in diabetic  
55  
56 patients. *Caspian J Internal Med* 2014;5:40.  
57  
58  
59 51. Holick MF. Vitamin D deficiency. *New Eng J Med* 2007;357:266-281.  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
52. Johnson JA, Grande JP, Roche PC, Campbell RJ, Kumar RJ. Immunolocalization of the calcitriol receptor, calbindin-D28k and the plasma membrane calcium pump in the human eye. *Curr Eye Res* 1995;14:101-108.
53. Aksoy H, Akçay F, Kurtul N, Baykal O, Avcı B. Serum 1, 25 dihydroxy vitamin D (1, 25 (OH) 2D3), 25 hydroxy vitamin D (25 (OH) D) and parathormone levels in diabetic retinopathy. *Clinic Biochem* 2000;33:47-51.
54. Alsalem JA, Patel D, Susarla R, Coca-Prados M, Bland R, Walker EA, Rauz S, Wallace GR. Characterization of vitamin D production by human ocular barrier cells. *Invest Ophthalmol Vis Sci* 2014;55:2140-2147.
55. Berridge MJ. Vitamin D deficiency and diabetes. *Biochem J* 2017;474:1321-1332.

1  
2  
3 TABLE 1: Characteristics of the Study Population according to Diabetic Status  
4

5  
6 TABLE 2: MPOD according to Demographic and Behavioural characteristics in a  
7  
8 Diabetic Population (normalized MPOD).  
9

10  
11  
12 TABLE 3: MPOD according to Anthropometric and Clinical Biomarkers in a Diabetic  
13  
14 Population (normalized MPOD).  
15

16  
17 TABLE 4: MPOD according to Serum Biomarkers in a Diabetic Population  
18  
19 (normalized MPOD).  
20

21  
22 TABLE 5: Multivariate Relationship between Behavioral, Anthropometric, Clinical,  
23  
24 Serum Biomarkers and MPOD in a Diabetic population (n=188).  
25

26  
27  
28 Figure 1. Population included in analysis  
29

30  
31 Abbreviations: AMD, age-related macular degeneration; MPOD, macular pigment  
32  
33 optical density, n, number of participants; TILDA, The Irish Longitudinal Study on  
34  
35 Ageing; VA, Visual Acuity.  
36

37  
38 Figure 2: Box plots of MPOD by (A) Smoking status (B) Hypertension status (C)  
39  
40 Triglyceride over High Density Lipoprotein ratio (D) Vitamin D 25(OH) D serum  
41  
42 levels.  
43

44  
45 Figure 3: Scatterplot showing a significant positive relationship between normalized  
46  
47 MPOD and Vitamin D (25(OH) D) serum levels.  
48  
49

50  
51 **Word Count:** 5,023  
52

53 **Abstract:** 281  
54

55 **Tables:** 5  
56

57 **Figures:** 3  
58  
59  
60






Figure 1. Population included in analysis

Abbreviations: AMD, age-related macular degeneration; MPOD, macular pigment optical density, n, number of participants; TILDA, The Irish Longitudinal Study on Ageing; VA, Visual Acuity.

**Table 1: Characteristics of the Study Population according to Diabetic Status**

	Normal Controls (n=2594)	Type 2 Diabetics (n=188)	<i>p</i>
<b>Demographic Factors</b>			
Age years (Mean (SD))	61.40(7.62)	64.73(8.32)	0.0001*
Age category years † (%)			
50-64	68.12%	51.06%	0.0001 ‡
65-74	24.94%	35.64%	
>75	6.94%	13.30%	
Sex (%)			
Male	43.79%	64.89%	0.0001 ‡
Female	56.21%	35.11%	
Education (%)			
Primary	18.81%	22.34%	0.174 ‡
Secondary	41.60%	44.68%	
Third level	39.59%	32.98%	
<b>Behavioral Factors</b>			
Smoking (%)			
Current	13.42%	14.89%	0.027 ‡
Past	39.36%	47.87%	
Never	47.22%	37.23%	
Alcohol (%)			
Yes	78.83%	72.87%	0.130 ‡
No	18.47%	22.87%	
NA	6.51%	3.72%	

Exercise (%)			
Low	37.90%	54.25%	0.0001 ‡
Moderate	30.07%	28.19%	
High	32.03%	17.55%	
<b>Anthropometric &amp; Clinical Biomarkers (Mean (SD))</b>			
BMI, kg/m <sup>2</sup>	27.98 (4.42)	32.32 (6.25)	0.0001*
WC, cm	93.19 (12.83)	105.47 (13.74)	0.0001*
WHtR	0.56 (0.070)	0.63 (0.08)	0.0001*
WHpR	0.894 (0.083)	0.96 (0.08)	0.0001*
Hypertensive (untreated)	5.82%	2.66%	0.0001 ‡
Hypertensive (treated)	24.79%	52.19%	
Normotensive	69.39%	44.15%	
MPOD** (Mean (SD))	0.223(0.161)	0.20(0.148)	0.047††
Cataracts (%)	6.51%	13.83%	0.0001 ‡
<b>Serum Biomarkers (Mean (SD))</b>			
TC mmol/L	5.24(1.04)	4.27(1.06)	0.0001*
HDL mmol/L	1.59(0.44)	1.27(0.33)	0.0001*
LDL mmol/L	3.01(0.92)	2.24(0.89)	0.0001*
TG mmol/L	1.66(1.03)	1.94(1.11)	0.0001*
TC/HDL Ratio	3.46(0.91)	3.473(0.92)	0.676*
TG/HDL Ratio	1.19(0.961)	1.68(1.12)	0.0001*
Non-HDL (TC-HDL) Ratio	3.65(0.946)	2.99(0.950)	0.0001*
Vitamin D nmol/L	59.91(25.86)	51.90(22.72)	0.0001*
CRP mg/L	2.83(6.95)	5.23(11.94)	0.0001*
HbA1c %	5.06(0.27)	6.22(0.934)	0.0001*

‡ Chi-square test; \*Kruskal–Wallis test; ††One-way analysis of variance (ANOVA);

MPOD sqrt; *P* values reflect the probability associated with the given F statistic. Data is weighted. Sig., significance.

†Age: the age division corresponds to groupings used in previously published cohort studies.<sup>32</sup>

\*\*MPOD, *P* values are reported using MPOD square root transformation (sqrt).

Abbreviations: BMI-body mass index; kg/m<sup>2</sup>- kilograms per metre squared; NA – non-applicable; WC-waist circumference; cm - centimetres; WHtR-waist-to-height ratio; WHpR-waist-to-hip ratio. HbA1c-glycated hemoglobin; TC-Total cholesterol; HDL-High density lipoprotein; LDL-Low density lipoprotein; TG-Triglycerides; Non HDL- Total cholesterol minus HDL; CRP-C-reactive protein; mmHg- millimetres of mercury; mmol/L -millimoles per litre; nmol/L -nanomols per litre; mg/L-micrograms per litre. Normotensive ( $\leq 140$  mmHg systolic;  $\leq 90$  mmHg diastolic); Hypertensive ( $> 140$  mmHg systolic;  $> 90$  mmHg diastolic).

---

**Table 2: MPOD according to Demographic and Behavioural characteristics in a Diabetic Population (normalized MPOD)**

	n	Mean (SD)	25 <sup>th</sup>	50 <sup>th</sup>	75 <sup>th</sup>	sig
	188	MPOD				<i>p</i>
<b>Demographic &amp; Behavioural Factors</b>						
<b>Age (Mean (SD))</b>						
50-64	96	0.194 (0.148)	0.073	0.160	0.318	0.579††
65-74	67	0.204 (0.162)	0.087	0.197	0.276	
75-89	25	0.210 (0.11)	0.131	0.191	0.263	
<b>Sex (Mean (SD))</b>						
Male	122	0.201 (0.146)	0.088	0.180	0.282	0.701††
Female	66	0.197 (0.153)	0.074	0.167	0.301	
<b>Education (Mean (SD))</b>						
Primary/none	42	0.168 (0.135)	0.067	0.132	0.237	0.342††
Secondary	84	0.206 (0.152)	0.089	0.180	0.290	
Tertiary/higher	62	0.212 (0.151)	0.087	0.020	0.323	
<b>Smoker (Mean (SD))</b>						
Current smoker	28	0.124 (0.113)	0.043	0.089	0.169	0.003††
Past smoker	90	0.190 (0.151)	0.087	0.170	0.265	
Never smoked	70	0.235 (0.148)	0.108	0.218	0.342	
<b>Alcohol (Mean (SD))</b>						
Yes	137	0.210 (0.157)	0.087	0.178	0.308	0.120††
No	43	0.170 (0.126)	0.051	0.172	0.259	
<b>Exercise (Mean (SD))</b>						
Low	102	0.196 (0.152)	0.084	0.180	0.264	0.414††
Moderate	53	0.220 (0.148)	0.107	0.182	0.324	
High	33	0.177 (0.137)	0.061	0.138	0.290	

1  
2  
3  
4  
5 ††ANOVA was used to check for MPOD differences according to demographic and behavioural  
6 factors. *P* values are reported using MPOD square root transformation (sqrt) (normalized MPOD)  
7 and reflect the probability associated with the given F statistic. Data is weighted. Sig., significance.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---

For Peer Review Only

**TABLE 3: MPOD according to Anthropometric and Clinical Biomarkers in a Diabetic Population (normalized MPOD)**

	n	Mean (SD)	25 <sup>th</sup>	50 <sup>th</sup>	75 <sup>th</sup>	sig <i>p</i>
<b>Anthropometric &amp; Clinical Biomarkers</b>						
<b>BMI (kg/m<sup>2</sup>)</b>						
Ideal ( $\leq 30$ )	122	0.200 (0.148)	0.087	0.177	0.304	0.964 <sup>††</sup>
Excess ( $>30$ )	66	0.199 (0.150)	0.075	0.180	0.262	
<b>WC (cm)</b>						
Ideal ( $\leq 102$ M, $\leq 88$ F)	55	0.224 (0.140)	0.110	0.208	0.337	0.101 <sup>††</sup>
Excess ( $>102$ M, $>88$ F)	132	0.191 (0.151)	0.076	0.162	0.264	
<b>WHpR</b>						
Ideal ( $\leq 1.00$ M, $\leq 0.85$ F)	84	0.222 (0.153)	0.090	0.210	0.305	0.075 <sup>††</sup>
Excess ( $>1.00$ M, $>0.85$ F)	103	0.183 (0.142)	0.072	0.138	0.259	
<b>WHtR</b>						
Ideal ( $\leq 0.57$ M, $\leq 0.53$ F)	45	0.237 (0.164)	0.088	0.228	0.379	0.073 <sup>††</sup>
Excess ( $>0.57$ M, $>0.53$ F)	142	0.189 (0.142)	0.086	0.172	0.267	
<b>Blood Pressure (mmHg)</b>						
Normotensive ( $\leq 140/90$ )	83	0.228 (0.166)	0.090	0.210	0.324	0.043 <sup>††</sup>
Hypertensive ( $>140/90$ )	105	0.177 (0.130)	0.075	0.138	0.259	
<b>Diabetic Retinopathy</b>						
Yes	10	0.151 (0.134)	0.047	0.091	0.231	0.256 <sup>††</sup>
No	152	0.204 (0.149)	0.088	0.180	0.296	
<b>Cataracts</b>						
Yes	26	0.150 (0.108)	0.087	0.180	0.304	0.068 <sup>††</sup>

No 161 0.206 (0.153) 0.054 0.118 0.231

---

†† ANOVA was used to check for MPOD differences among anthropometric and physical biomarkers. *P* values are reported using MPOD square root transformation (sqrt) (normalized MPOD) and reflect the probability associated with the given F statistic. Data is weighted. Sig., significance.

The following cut-offs were applied to indicate ideal or excess obesity measures and normotensive/hypertension for the following variables: BMI-body mass index; [ideal  $\leq 30$ ; excess  $> 30 \text{ kg/m}^2$  - kilograms per metre squared; WC-waist circumference; ideal  $\leq 88 \text{ F}$ ;  $\leq 102 \text{ M}$ ; excess  $> 88 \text{ F}$ ;  $>102 \text{ M cm}$  - centimetres; WHtR-waist-to-height ratio; ideal  $\leq 0.53 \text{ F}$ ;  $\leq 0.57 \text{ M}$ ; excess  $>0.57 \text{ F}$ ;  $>0.53 \text{ M}$ ; WHpR-waist-to-hip ratio; ideal  $\leq 0.85 \text{ F}$ ;  $\leq 1.00 \text{ M}$ ; excess  $> 0.85 \text{ F}$ ;  $>1.00 \text{ M}$ ; M=Male; F=Female; <sup>27</sup> Normotensive ( $\leq 140 \text{ mmHg}$  systolic;  $\leq 90 \text{ mmHg}$  diastolic); Hypertensive ( $>140 \text{ mmHg}$  systolic;  $>90 \text{ mmHg}$  diastolic).



**TABLE 4: MPOD according to Serum Biomarkers in a Diabetic Population**  
(normalized MPOD)

	n	Mean (SD)	25 <sup>th</sup>	50 <sup>th</sup>	75 <sup>th</sup>	sig
	188	MPOD				<i>p</i>
<b>Serum Biomarkers</b>						
<b>TC (mmol/L)</b>						
Ideal ≤ 5.00	141	0.207 (0.152)	0.088	0.182	0.304	0.287††
High >5.00	46	0.177 (0.138)	0.068	0.163	0.260	
<b>HDL (mmol/L)</b>						
Ideal >1.6	27	0.203 (0.138)	0.089	0.184	0.275	0.785††
Low ≤ 1.6	160	0.199 (0.1510)	0.085	0.173	0.296	
<b>LDL (mmol/L)</b>						
Ideal ≤ 2.6	127	0.20 (0.147)	0.076	0.179	0.297	0.946††
High >2.6	10	0.199 (0.154)	0.087	0.0174	0.276	
<b>TG (mmol/L)</b>						
Ideal ≤ 1.7	97	0.203 (0.147)	0.099	0.177	0.285	0.491††
High >1.7	90	0.195 (0.151)	0.069	0.179	0.301	
<b>Non HDL (mmol/L)</b>						
Ideal ≤ 3.4	132	0.202 (0.146)	0.088	0.178	0.303	0.671††
High >3.4	55	0.194 (0.157)	0.072	0.172	0.263	
<b>TG/HDL C Ratio</b>						
Ideal ≤ 1.74	118	0.215 (0.152)	0.100	0.181	0.314	0.039††
High >1.74	69	0.172 (0.140)	0.053	0.119	0.248	
<b>Vitamin D (nmol/L)</b>						
Deficient ≤ 50	96	0.173 (0.148)	0.056	0.181	0.234	0.006††

Sufficient >50	91	0.226 (0.145)	0.103	0.209	0.336	
<b>CRP (mg/L)</b>						
Ideal ≤ 3.0	113	0.213 (0.158)	0.088	0.181	0.298	0.120††
High >3.0	74	0.178 (0.130)	0.069	0.167	0.262	
<b>HbA1c (%)</b>						
≤ 6.0	77	0.203 (0.160)	0.081	0.173	0.295	0.728††
> 6.0	97	0.190 (0.139)	0.081	0.177	0.259	

††ANOVA was used to check for MPOD differences among serum biomarkers. *P* values are reported using MPOD square root transformation (sqrt) (normalized MPOD) and reflect the probability associated with the given F statistic. Data is weighted. Sig., significance.

The following cut-offs were applied to serum levels: HDL, high density lipoprotein; [high risk ≤ 1.6; low risk > 1.6 millimoles per litre (mmol/L)]; LDL, low density lipoprotein; [high risk > 2.6; low risk ≤ 2.6 mmol/L]; TC, total cholesterol; [high risk > 5.00; low risk ≤ 5.00 mmol/L]; TG, triglycerides; [high risk > 1.7; low risk ≤ 1.7 mmol/L]; TG/HDL, triglyceride to high density lipoprotein ratio; [high risk > 1.74; low risk ≤ 1.74 mmol/L]; TC/HDL, total cholesterol to high density lipoprotein ratio; [high risk > 3.5; low risk ≤ 3.5 mmol/L]; Non-HDL, total cholesterol minus high density lipoprotein; [high risk > 3.4; low risk ≤ 3.4 mmol/L] as per 2016 ESC/EAS guidelines;<sup>28</sup> serum vitamin D (25(OH) D) levels in nanomoles per litre (nmol/L) [deficient ≤ 50; sufficient > 50 nmol/L] as per IOM vitamin D guidelines;<sup>29</sup> serum CRP levels in micrograms per litre (mg/L) [high > 3.00 mg/L; ideal ≤ 3.00 mg/L];<sup>30</sup> and HbA1c (glycated hemoglobin) in millimoles per mol (mmol/mol) [high > 6.00 %; ideal ≤ 6.00 % (42.1 mmol/mol) as per American Diabetes Association guidelines.<sup>24</sup>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2A: Box plots of MPOD by (A) Smoking status (B) Hypertension status (C) Triglyceride over High Density Lipoprotein ratio (D) Vitamin D 25(OH) D serum levels.

224x132mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2B: Box plots of MPOD by (A) Smoking status (B) Hypertension status (C) Triglyceride over High Density Lipoprotein ratio (D) Vitamin D 25(OH) D serum levels.

224x132mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2C: Box plots of MPOD by (A) Smoking status (B) Hypertension status (C) Triglyceride over High Density Lipoprotein ratio (D) Vitamin D 25(OH) D serum levels.

224x132mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2D: Box plots of MPOD by (A) Smoking status (B) Hypertension status (C) Triglyceride over High Density Lipoprotein ratio (D) Vitamin D 25(OH) D serum levels.

224x132mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3: Scatterplot showing a significant positive relationship between normalized MPOD and Vitamin D (25(OH) D) serum levels.

224x132mm (300 x 300 DPI)

**TABLE 5: Multivariate Relationship between Behavioral, Anthropometric, Clinical, Serum Biomarkers and MPOD in a Diabetic population (n=188)**

Independent Variable	Unstandardized Beta Coefficient	Std Error	<i>T</i>	MPOD sqrt <i>p</i>
Constant	0.428	0.197	2.175	0.031
Age	0.001	0.002	0.700	0.485
Sex* (Female)	-0.007	0.025	-0.259	0.796
Smoking†				
Past	-0.028	0.031	-0.913	0.363
Current	-0.097	0.042	-2.316	0.022
WHtR	-0.192	0.183	-1.046	0.297
Cataracts‡ (Yes)	-0.078	0.039	-1.988	0.049
Vitamin D nmol/L	0.001	0.001	2.204	0.029
CRP mg/L	0.001	0.001	1.382	0.169
TG/HDL Ratio	-0.015	0.013	-1.170	0.244
HbA1c %	-0.006	0.017	-0.373	0.710
Duration (years)	0.003	0.003	1.093	0.276
Retinopathy†† (Yes)	-0.092	0.058	1.585	0.115
Hypertension ‡‡ (No)	0.035	0.027	1.302	0.195

$r^2 = 0.185$ ;  $F = 2.545$ ;  $p = 0.003$ . Dependent variable = MPOD sqrt (normalized MPOD); Data is weighted. Std. Error, Standard Error.

\*Male = control group; † Never smoked = control group; ‡ No Cataracts = control group;

††No Diabetic Retinopathy = Control group; ‡‡ Hypertension= Control group.



1  
2  
3 Abbreviations: CRP - C-reactive protein; HbA1c- glycated hemoglobin; mg/L – micrograms per litre;  
4  
5 nmol/L – nanomoles per litre; WHtR- waist to height ratio; TG/HDL- triglyceride to high density  
6  
7 lipoprotein ratio.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review Only